Latest News
Baxter International and Halozyme Therapeutics introduces Hyqvia in US
22 October 2014 - Baxter International, a medical devices, pharmaceuticals and biotechnology company, and Halozyme Therapeutics, a biopharmaceutical company, have introduced Hyqvia in the United States, it was reported yesterday.

The product has been launched as a subcutaneous immunoglobulin treatment for adult patients with primary immunodeficiency. It includes Immune Globulin Infusion 10% (Human) (IG 10%) and recombinant human hyaluronidase developed by Halozyme.

The US Food and Drug Administration approved the product in September 2014. University of Texas Southwestern Medical School clinical professor of paediatrics and clinical investigator on the HYQVIA clinical trial, Richard Wasserman, stated that Hyqvia will have a significant impact on the treatment of primary immunodeficiency.

Login
Username:

Password: